Our first hypothesis was supported: the effect of baseline amyloid pathology on future executive function performance was partially serially mediated by tau pathology and neurodegeneration, although the tau-independent (amyloid → mneurodegeneration → eexecutive function) pathway explained the greatest proportion of variance in the total amyloid effect. The gene discussed is MAPT; the disease is amyloidosis.